Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Set & Setting

Esketamine for Set & Setting

1 paper and 0 clinical trials exploring esketamine as a treatment for set & setting.

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationApproximately 264 million individuals worldwide suffer from depression, with many seeking innovative treatment options such as psychedelic-assisted therapy.

Set & Setting

The concept of 'set and setting' is critical in psychedelic research, influencing therapeutic outcomes in clinical environments. Creating optimal conditions is essential for maximising the efficacy and safety of psychedelic-assisted therapies, particularly in the context of mental health disorders.

Full Set & Setting profile

Academic Research

1 paper
Open Accessindividual

Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study

This qualitative IPA study of 17 patients with treatment‑resistant depression found that the key determinant of esketamine session experience and subsequent outcomes was patients’ ability to “let go” of control during overwhelming psychoactive effects, which was strongly shaped by preparation, emotional/physical support, and the treatment setting. The authors recommend better pre‑session education, optimised settings and targeted training for nurses/support staff to facilitate surrender and improve quality of care.

Published
November 25, 2022
Journal
Frontiers in Psychiatry
Authors
Breeksema, J. J., Niemeijer, A. R., Kuin, B., Veraart, J. K. E., Kamphuis, J., Schimmel, N., van den Brink, W., Vermetten, E., Schoevers, R. A.

Clinical Trials

0 trials

No clinical trials have been tagged with both Esketamine and Set & Setting yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Esketamine papers Search all Set & Setting trials Full Esketamine profile Full Set & Setting profile